• Something wrong with this record ?

GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy

ML. Cediel, M. Stawarski, X. Blanc, L. Nosková, M. Magner, K. Platzer, J. Gburek-Augustat, D. Baldridge, JN. Constantino, E. Ranza, B. Bettler, SE. Antonarakis

. 2022 ; 109 (10) : 1885-1893. [pub] 20220913

Language English Country United States

Document type Journal Article

E-resources Online Full text

NLK Cell Press Free Archives from 1997-01-01 to 6 months ago
Free Medical Journals from 1949 to 6 months ago
PubMed Central from 1949 to 6 months ago
Europe PubMed Central from 1949 to 6 months ago
Open Access Digital Library from 2005-01-01

GABAB receptors are obligatory heterodimers responsible for prolonged neuronal inhibition in the central nervous system. The two receptor subunits are encoded by GABBR1 and GABBR2. Variants in GABBR2 have been associated with a Rett-like phenotype (MIM: 617903), epileptic encephalopathy (MIM: 617904), and milder forms of developmental delay with absence epilepsy. To date, however, no phenotypes associated with pathogenic variants of GABBR1 have been established. Through GeneMatcher, we have ascertained four individuals who each have a monoallelic GABBR1 de novo non-synonymous variant; these individuals exhibit motor and/or language delay, ranging from mild to severe, and in one case, epilepsy. Further phenotypic features include varying degrees of intellectual disability, learning difficulties, autism, ADHD, ODD, sleep disorders, and muscular hypotonia. We functionally characterized the four de novo GABBR1 variants, p.Glu368Asp, p.Ala397Val, p.Ala535Thr, and p.Gly673Asp, in transfected HEK293 cells. GABA fails to efficiently activate the variant receptors, most likely leading to an increase in the excitation/inhibition balance in the central nervous system. Variant p.Gly673Asp in transmembrane domain 3 (TMD3) renders the receptor completely inactive, consistent with failure of the receptor to reach the cell surface. p.Glu368Asp is located near the orthosteric binding site and reduces GABA potency and efficacy at the receptor. GABA exhibits normal potency but decreased efficacy at the p.Ala397Val and p.Ala535Thr variants. Functional characterization of GABBR1-related variants provides a rationale for understanding the severity of disease phenotypes and points to possible therapeutic strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033119
003      
CZ-PrNML
005      
20230131151207.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ajhg.2022.08.010 $2 doi
035    __
$a (PubMed)36103875
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cediel, Maria Lucia $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland
245    10
$a GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy / $c ML. Cediel, M. Stawarski, X. Blanc, L. Nosková, M. Magner, K. Platzer, J. Gburek-Augustat, D. Baldridge, JN. Constantino, E. Ranza, B. Bettler, SE. Antonarakis
520    9_
$a GABAB receptors are obligatory heterodimers responsible for prolonged neuronal inhibition in the central nervous system. The two receptor subunits are encoded by GABBR1 and GABBR2. Variants in GABBR2 have been associated with a Rett-like phenotype (MIM: 617903), epileptic encephalopathy (MIM: 617904), and milder forms of developmental delay with absence epilepsy. To date, however, no phenotypes associated with pathogenic variants of GABBR1 have been established. Through GeneMatcher, we have ascertained four individuals who each have a monoallelic GABBR1 de novo non-synonymous variant; these individuals exhibit motor and/or language delay, ranging from mild to severe, and in one case, epilepsy. Further phenotypic features include varying degrees of intellectual disability, learning difficulties, autism, ADHD, ODD, sleep disorders, and muscular hypotonia. We functionally characterized the four de novo GABBR1 variants, p.Glu368Asp, p.Ala397Val, p.Ala535Thr, and p.Gly673Asp, in transfected HEK293 cells. GABA fails to efficiently activate the variant receptors, most likely leading to an increase in the excitation/inhibition balance in the central nervous system. Variant p.Gly673Asp in transmembrane domain 3 (TMD3) renders the receptor completely inactive, consistent with failure of the receptor to reach the cell surface. p.Glu368Asp is located near the orthosteric binding site and reduces GABA potency and efficacy at the receptor. GABA exhibits normal potency but decreased efficacy at the p.Ala397Val and p.Ala535Thr variants. Functional characterization of GABBR1-related variants provides a rationale for understanding the severity of disease phenotypes and points to possible therapeutic strategies.
650    _2
$a lidé $7 D006801
650    12
$a epilepsie $x genetika $7 D004827
650    _2
$a GABA $x metabolismus $7 D005680
650    _2
$a HEK293 buňky $7 D057809
650    12
$a mentální retardace $x genetika $7 D008607
650    12
$a malformace nervového systému $7 D009421
650    12
$a neurovývojové poruchy $x genetika $7 D065886
650    12
$a receptory GABA-B $x genetika $7 D018080
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stawarski, Michal $u Department of Biomedicine, Pharmazentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
700    1_
$a Blanc, Xavier $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland
700    1_
$a Nosková, Lenka $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Magner, Martin $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Department of Pediatrics, First Faculty of Medicine, Charles University and University Thomayer Hospital in Prague, Prague, Czech Republic
700    1_
$a Platzer, Konrad $u Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany
700    1_
$a Gburek-Augustat, Janina $u Division of Neuropaediatrics, Hospital for Children and Adolescents, University Hospital Leipzig, Leipzig, Germany
700    1_
$a Baldridge, Dustin $u Washington University in St. Louis, St. Louis, MO, USA
700    1_
$a Constantino, John N $u Washington University in St. Louis, St. Louis, MO, USA
700    1_
$a Ranza, Emmanuelle $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland
700    1_
$a Bettler, Bernhard $u Department of Biomedicine, Pharmazentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
700    1_
$a Antonarakis, Stylianos E $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland. Electronic address: stylianos.antonarakis@medigenome.ch
773    0_
$w MED00000254 $t American journal of human genetics $x 1537-6605 $g Roč. 109, č. 10 (2022), s. 1885-1893
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36103875 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151203 $b ABA008
999    __
$a ok $b bmc $g 1891714 $s 1184454
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 109 $c 10 $d 1885-1893 $e 20220913 $i 1537-6605 $m American journal of human genetics $n Am J Hum Genet $x MED00000254
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...